PARIS, June 25 (Reuters) - French drugmaker Sanofi is in the “very early stages” of considering the sale of a portfolio of older drugs, managers told an internal meeting on Wednesday, according to union representatives who were present.
People familiar with the matter had told Reuters in April that Sanofi was looking to part with drugs that could fetch $7-8 billion as it seeks to shed non-core assets and focus on high-growth areas.
Help employers find you! Check out all the jobs and post your resume.
